Novo Nordisk A/S which can be found using ticker (NVO) now have 5 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 174.13 and 120.09 suggesting an average Analsyt target price of $153.12. Given that the stocks previous close was at $163.52 this indicates there is a potential downside of -6.4%. It’s also worth noting that there is a 50 day moving average of $146.41 and the 200 moving average now moves to $123.25. The total market capitalization for the company now stands at $377,019m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $353,040m based on the market consensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
The company has a dividend yield of 1.05% with the ex dividend date set at 24-3-2023 (DMY).
Other points of data to note are a P/E ratio of 46.7, revenue per share of 78.12 and a 21.69% return on assets.
